Quick Answer
Entrada Therapeutics, Inc. reported Shares Outstanding of 38.28 million shares for fiscal year 2025.
Entrada Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 38.28M | +1.9% |
| 2024 | 37.57M | +12.4% |
| 2023 | 33.44M | +6.5% |
| 2022 | 31.39M | +0.5% |
| 2021 | 31.22M | +2409.7% |
| 2020 | 1.24M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 38.22M | +2.2% | +0.5% |
| June 30, 2025 | 38.03M | +2.3% | +0.2% |
| March 31, 2025 | 37.94M | +12.9% | +1.0% |
| December 31, 2024 | 37.57M | +12.4% | +0.5% |
| September 30, 2024 | 37.40M | +12.2% | +0.6% |
| June 30, 2024 | 37.17M | +11.9% | +10.6% |
| March 31, 2024 | 33.60M | +1.4% | +0.5% |
| December 31, 2023 | 33.44M | +6.5% | +0.3% |
- Entrada Therapeutics, Inc. showed an increase of +1.9% in Shares Outstanding compared to the prior fiscal year.
- Over the 2020–2025 period, Entrada Therapeutics, Inc.’s shares outstanding has grown by 2977.2% (from 1.24 million shares to 38.28 million shares).
- The most recent figure is from Entrada Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: